Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis

Multicenter, Open Label Study to Evaluate the Predictability of Early Response to Certolizumab Pegol (in Combination With Methotrexate) as Confirmed at Week 52 in Subjects With Moderate-severe Rheumatoid Arthritis (RA)

The study aims to evaluate the predictability of early response to Certolizumab pegol in combination with Methotrexate at one year in patients with moderate to severe rheumatoid arthritis.

Inclusion Criteria:

• diagnosis of adult-onset Rheumatoid Arthritis (RA) for a duration of at least 6 months but not longer than 5 years
• positive Rheumatoid Factor (RF) and/or positive anti Cyclic Citrullinated Peptide (anti-CCP)
• active RA disease
• subjects must have failed at least one traditional Disease Modifying Anti-Rheumatic Drug (DMARD).
• subject is naïve to RA related biologics

Exclusion Criteria:

• a diagnosis of any other inflammatory arthritis
• history of infected joint prosthesis, or other significant infection
• known Tuberculosis (TB) disease or high risk of acquiring TB infection